Mir-192-5p Expression in MDS progenitor cells during Response to Azacitidine and Lenalidomide Therapy

Results were then validated by Real-Time PCR, also used to examine the gene expression, and miRNA targets were studied by dual Luciferase assay. Real-Time PCR analyses confirmed the modulation of miR-192-5p and an altered expression of BCL-2 (target of miR-192-5p, proven in vitro by dual Luciferase assays). All in all, this study shows that AZA+LEN therapy in MDS affects the expression of miR-192-5p in MDS progenitor cells, whose high level at T4 is associated with higher OS and LFS in responder patients. [...]we showed that miR-192-5p specifically targets and inhibits BCL-2, hinting at a regulation of MDS proliferation and apoptosis.